AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02277184 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Each vial contains 10 mg of DDP, 19 mg of sodium chloride, 100 mg of mannitol, and hydrochloric acid for pH adjustment. One vial is reconstituted with 10 ml of sterile water. The pH range will be 3.5 to 4.5.~Cisplatin will be given as a bolus, infused over 1-2 hours along with appropriate hydration and anti-emetics.~Reconstituted solution of cisplatin is stable for 20 hours when stored at 27°C and should be protected from light if not used within 6 hours. The vials and injection should not be refrigerated. Cisplatin has been shown to react with aluminum needles, producing a black precipitate within 30 minutes.
Study NCT02277184 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Intensity Modulated Radiotherapy (IMRT)
Description: Immobilization should be performed to ensure daily reproducibility of setup.Treatment planning CT scans will be required to define tumor, clinical and planning target volumes.The treatment planning CT scan should be performed with IV contrast. All tissues to be irradiated must be included in the CT scan.~Targets are defined as primary (requiring a higher dose) and secondary (targets at lower risk requiring a lower dose). The primary target is the PTV3 of the primary tumor and lymph nodes containing clinical or radiographic evidence of metastases. The secondary target is the PTVs consist of an area at intermediate risk (PTV2) and that containing the lowest risk of lymph node involvement (PTV2).~The treatment plan will be based on an analysis of the volumetric dose, including dose volume histogram (DVH) analyses of the PTV and critical normal structures. Inverse planning will be utilized to deliver optimal dose to the PTVs while excluding noninvolved normal tissue.
Study NCT03202420 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: TOPS
Description: Take Off Pounds Sensibly (TOPS) is a national, nonprofit, peer-led, group-based, weight loss program that offers a comprehensive program on diet and physical activity with group support for weight management.
Study NCT01825304 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: titrated setting peep
Description: titrated setting peep according to esophageal pressure in experimental group; setting peep on the patient's PaO2 and FiO2 in control group.
Study NCT01825304 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: titrated setting peep
Description: titrated setting peep according to esophageal pressure in experimental group; setting peep on the patient's PaO2 and FiO2 in control group.
Study NCT02302846 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ixazomib
Description: 4 mg by mouth on Days 1, 8 and 15 of each 28-day cycle.
Study NCT01450813 — intervention group
Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Saline 0.06 ml/kg
Description: IV Infusion x1 prior to laryngoscopy
Study NCT01450813 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rocuronium 0.2 mg/kg
Description: IV Infusion x1 prior to laryngoscopy
Study NCT01450813 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rocuronium 0.4 mg/kg
Description: IV Infusion x1 prior to laryngoscopy
Study NCT01450813 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rocuronium 0.6 mg/kg
Description: IV Infusion x1 prior to laryngoscopy
Study NCT00917124 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: INVOS
Description: Monitoring cerebral oxygenation (rSO2) with INVOS. When rSO2 decline occur it can be responded with simple interventions to prevent a brain injury including: repositioning of the head or perfusion cannulae to avoid mechanical obstruction of cerebral blood flow, increasing arterial carbon dioxide tension within normal referent values, increasing oxygen inspiration concentration to maintain adequate tissue oxygen saturation, increasing arterial blood pressure, pump flow rate and cardiac index, temperature decreasing and increasing of anesthetic depth to reduce cerebral oxygen consumption and blood transfusion if hematocrit decreases below 22%.~None of the interventions are outside the range of good clinical practice.
Study NCT02972983 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daptomycin
Description: Adjuvant therapy for up to five days
Study NCT02972983 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT01935089 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegylated Interferon alpha 2b
Description: 1µg/kg/week
Study NCT01253096 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intratumoral injections of L19IL2
Description: Patients will be treated with intratumoral injections of L19IL2 1-3 x weekly. The maximum cumulative dose per week is 20 MioIU. Treatment duration is up to 20 weeks.
Study NCT02104661 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxcarbazepine
Description: Oxcarbazepine 150mg tablet, over encapsulated and back-filled with Microcrystalline Cellulose/Magnesium Stearate 1%.
Study NCT02104661 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo in a matched capsule containing Microcrystalline Cellulose/Magnesium Stearate 1%.
Study NCT03131284 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intensive education
Description: For each well visit within the first two years of their child's life, parents are provided with oral and written information on behaviors to adopt for their child to be protected from obesity: breast feeding, feeding on demand, responsive feeding, correct time of introduction of complementary feeding, portions shaped on the child's appetite, avoiding pressing the child to eat more and rewarding or punishing the child with food, avoiding added sugar and beverages other than milk and water, practicing active game with the child, alternating protein sources correctly and avoiding protein excess. Written menus examples and coloured photos of average portions are given for complementary feeding. Parents are also provided with information about health consequences of childhood obesity.
Study NCT00973583 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: vitamin D
Description: vitamin D3 400 IU daily
Study NCT00973583 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo
Study NCT00115778 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IVIG
Description: 10% Caprylate/Chromatography Purified Intravenous Immunoglobulin 400 mg/kg IV every 4 weeks
Study NCT00115778 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: 0.1% Albumin in an equal volume to the investigational product
Study NCT03713684 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Efpeglenatide SAR439977
Description: Pharmaceutical form: solution for injection Route of administration: subcutaneous
Study NCT03713684 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Pharmaceutical form: solution for injection Route of administration: subcutaneous
Study NCT03713684 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Background therapy
Description: Lantus (Insulin Glargine), SC, once daily; OADs, administered as per investigator prescription and in accordance with local labeling.
Study NCT03713684 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Background therapy
Description: Lantus (Insulin Glargine), SC, once daily; OADs, administered as per investigator prescription and in accordance with local labeling.
Study NCT00385177 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SN2310 Injectable Emulsion
Description: Escalating doses given IV every three weeks
Study NCT03500991 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HER2-specific chimeric antigen receptor (CAR) T cell
Description: Autologous CD4 and CD8 T cells lentivirally transduced to express a HER2 specific chimeric antigen receptor (CAR) and EGFRt given via indwelling central nervous system (CNS) catheter
Study NCT01759524 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine
Study NCT00751946 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Trauma Adaptive Recovery Group Education and Therapy
Description: Trauma Affect Regulation: Guidelines for Education and Therapy (TARGET; Ford \& Russo, 2006) is a manualized gender-specific treatment for PTSD. The 12-session individual therapy version in the present study is being adapted for adolescent girls based on a parallel version for young mothers and a group version that has been field tested with more than 20 adolescent girls.~TARGET teaches a practical 7-step sequence of skills for processing and managing trauma-related reactions to current stressful experiences. The skills are designed in a sequence mirroring the three phases of complex traumatic stress disorder treatment (Ford, Courtois, Van der Hart, Nijenhuis \& Steele, 2005), summarized by an acronym FREEDOM. TARGET also uses creative arts activities: personalized lifelines via collage, drawing, poetry, and writing.
Study NCT04601727 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: 16srRNA pyrosequencing analysis of microbiota of saliva and faeces
Description: No intervention in this study
Study NCT03854578 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 1358894
Description: Film-coated tablet
Study NCT03854578 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo matching BI 1358894
Description: Film-coated tablet
Study NCT03854578 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Citalopram
Description: Film-coated tablet
Study NCT02603198 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: mepivacaine chloridrato epinephrine
Description: local anesthesia for tooth removal
Study NCT02603198 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: mepivacaine chloridrato levonordefrin
Description: local anesthesia for tooth removal
Study NCT03690713 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Fractional flow reserve, coronary flow reserve, and index of microcirculatory resistance
Description: The pressure sensor was positioned at the distal segment of a target vessel, and intracoronary nitrate was administered before each physiologic measurement. To derive resting mean transit time (Tmn), a thermodilution curve was obtained by using 3 injections (3-4 mL each) of room-temperature saline. Hyperemic proximal aortic pressure (Pa), distal arterial pressure (Pd), and hyperemic Tmn were measured during sustained hyperemia. CFR was calculated as resting Tmn/hyperemic Tmn. FFR was calculated as the lowest average of 3 consecutive beats during hyperemia. The uncorrected IMR was calculated by Pd × Tmn during hyperaemia. All IMR values were corrected by Yong's formula (Pa × Tmn × (\[1.35 × Pd/Pa\] - 0.32).
Study NCT01759524 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lidocaine
Study NCT00751946 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Enhanced Treatment As Usual
Description: Enhanced Treatment as Usual (ETAU) is a 12-session supportive therapy adapted from the Present Centered Therapy co-developed by the first author (McDonagh-Coyle, Friedman, McHugo, Ford, Mueser, \& Sengupta, 2005). In ETAU therapists invite the participant to talk about goals or problems that are important to her. The therapist's focus is on providing the core conditions of client centered psychotherapy (nonjudgmental acceptance, empathy, interpersonal warmth) and engaging the participant in a strengths-based solution-focused reflection on how she is successful (or has been in the past) in managing stressors, handling problems, achieving personal goals, and developing healthy relationships with peers, family, and other community members.
Study NCT04356521 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Lateral Sagittal Approach
Description: The US probe will be located medial to the coracoid process in the sagittal plane in the infraclavicular region, and then three cords of the brachial plexus will be viewed. Using the in-plane technique, bupivacaine 0.5% will be administered around the posterior cord (7ml), lateral cord (7ml), and medial cord (6ml).
Study NCT04356521 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Costoclavicular Approach
Description: The US probe will be placed parallel to the clavicle in the midclavicular area and tilted toward the cephalad and the axillary artery, and three cords will be viewed. A needle will be forwarded from lateral to medial with the in-plane technique, and 20 ml of bupivacaine 0.5% will be administered at the center of the three cords.
Study NCT00981786 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Brimonidine/timolol fixed combination drops added to travoprost
Description: twice daily administration
Study NCT00981786 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Brinzolamide/timolol fixed combination drops added to travoprost
Description: twice daily dosing
Study NCT04756102 — intervention group
Intervention type: OTHER
Intervention: Observation of their fetomaternal outcome
Description: observe the fetal outcome and maternal outcome
Study NCT04218032 — intervention group
Intervention type: DEVICE
Intervention: sphygmomanometer, SpyghmoCor, CNAP500
Description: blood pressure is measured with developed new non-invasive technology, oscillometry from the fingertip, and compared to non-invasive standard blood pressure measurement using a standard sphygmomanometer/SpyghmoCor device/CNAP500 device.
Study NCT03999801 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: RGX-314
Description: AAV8 vector containing a transgene for anti-VEGF Fab
Study NCT00406692 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zonisamide
Description: Week 1 (Wk1) -100 mg daily; Wk 2- 100 mg daily; Wk 3- 200 mg daily; Wk 4- 200 mg daily; Wk 5- 300 mg daily; Wk 6- 300 mg daily; Wk 7-11- 400 mg daily; Wk 12(Days 1-5) 300 mg daily; Wk 12 (Day 6-7) Week 13 (Days 1-3)- 200 mg daily; Week 13 (Days 4-7) - 100 mg daily.
Study NCT01359787 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mapracorat
Description: Daily topical application
Study NCT01359787 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle without active
Description: Daily topical application
Study NCT00821587 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cyclosporine
Description: Patients randomized to CsA had TAC discontinued and were treated with CsA at a dose of 2.0-4.0 mg/kg/day orally in two divided doses with target trough whole blood concentrations of 150-200 ng/ml.
Study NCT00821587 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tacrolimus
Description: Patients receiving TAC were treated with a dose of 0.08-0.12 mg/kg/day orally in two divided doses with target trough whole blood concentrations of 10-15 ng/ml for the first month post-transplant followed by 5-10 ng/ml thereafter. Immunosuppression was typically tapered to monotherapy (TAC alone) within 4-6 months of transplantation.
Study NCT02510040 — intervention group
Intervention type: DEVICE
Intervention: Prism
Description: Ground-in or Fresnel prism
Study NCT02510040 — intervention group
Intervention type: OTHER
Intervention: Orthoptic Exercises
Description: Orthoptic exercises- fusion, convergence, divergence, and others, including computer-based therapy
Study NCT02510040 — intervention group
Intervention type: PROCEDURE
Intervention: Eye Muscle Surgery
Description: * Bilateral medial rectus muscle resection surgery~* Single medial rectus muscle resection surgery~* Recess lateral rectus muscle resection medial rectus muscle surgery~* Bilateral lateral rectus muscle recession surgery~* Single lateral rectus muscle recession surgery~* Bilateral lateral rectus muscle resection surgery~* Single lateral rectus muscle resection surgery~* Recess medial rectus muscle resection lateral rectus muscle surgery~* Bilateral medial rectus muscle recession surgery~* Single medial rectus muscle recession surgery~* Vertical rectus muscle recession surgery~* Vertical rectus muscle mini-tenotomy (snip) surgery
Study NCT02510040 — intervention group
Intervention type: PROCEDURE
Intervention: Botox Injection
Description: Botulinum toxin injection
Study NCT04995770 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Praise Text Messages
Description: Texting messages with praise content, to positive reinforce medication adherence
Study NCT04393870 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Foccusing on Maryam's Flower
Description: Effect of Focusing on Maryam's Flower During the First Phase of the labor
Study NCT04483180 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Comparison of sweetener blends in liquid form (cross-over study)
Description: The aim is to compare the effects of different sweetener blends on glycemia, subjective appetite parameters and safety parameters when consumed in a beverage as part of a breakfast
Study NCT04483180 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Comparison of sweetener blends in liquid form (cross-over study)
Description: The aim is to compare the effects of different sweetener blends on glycemia, subjective appetite parameters and safety parameters when consumed in a beverage as part of a breakfast
Study NCT05305274 — intervention group
Intervention type: OTHER
Intervention: screening
Description: This study included 34,400 students, as part of the Tianjin Eye Study who performed a 3-year follow-up from 2019 to 2021. All participants underwent yearly noncycloplegic refraction and ocular examinations. Time-related changes in sphere, cylinder, and spherical equivalent (SE) measurements in both sexes were analyzed.
Study NCT01054599 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Memantine
Description: All subjects in the treatment group will be placed on memantine. The dosage of memantine will begin at 5mg once per day (qday), and increase by 5mg every week. The titration will continue over a period of 3 weeks until a goal of 10mg bid is reached. The dosing will increase slowly, to minimize the risk of side effects. The subject will then remain on memantine at 10mg bid for 10 weeks, until the conclusion of the first phase of the study. At the conclusion of the first 13 weeks, subjects will discontinue the treatment (memantine or placebo) and enter the open label phase.
Study NCT01054599 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Sugar Pill
Description: In the control arm of the study, subjects will take one placebo sugar pill per day for one week, then increase to one tablet twice per day for the following 12 weeks. At the end of this phase of the study, subjects will enter the open-label phase (unblinded treatment with memantine).
Study NCT01054599 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Memantine
Description: Open label: When the blinded phase is complete (Weeks 1-13), all subjects will receive open-label treatment with memantine (Weeks 14-26). The dosage of memantine will begin at 5mg once per day (qday), and increase by 5mg every week. The titration will continue over a period of 3 weeks until a goal of 10mg bid is reached. The dosing will increase slowly, to minimize the risk of side effects. The subject will then remain on memantine at 10mg bid for 10 weeks, until the conclusion of the study. At the conclusion of the study, subjects will discontinue the treatment.
Study NCT04204577 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apatinib Mesylate
Description: Evaluation of the efficacy and safety of simple local ablation, local ablation combined with apatinib, local ablation combined with apatinib and PD-1 antibody SHR-1210 for advanced liver cancer.
Study NCT00775697 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Montelukast
Description: the arm will be treated with Montelukast 4 mg die for 4 weeks
Study NCT00775697 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Montelukast
Description: montelukast 4 mg day for 4 weeks
Study NCT01326403 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tranexamic acid
Description: GROUP A - receive IV Tranexamic acid 1 gram upon diagnosis and consent in the emergency room. A second 1 gram in a slow drip during the next 8 hours.~GROUP B - IV Tranexamic acid 1 gram five minutes before skin incision and a second 1 gram in a slow drip during the next 8 hours.~Group C - A control group will only receive placebo in the emergency room and in the OR.
Study NCT01326403 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Tranexamic acid
Description: GROUP A - receive IV Tranexamic acid 1 gram upon diagnosis and consent in the emergency room. A second 1 gram in a slow drip during the next 8 hours.~GROUP B - IV Tranexamic acid 1 gram five minutes before skin incision and a second 1 gram in a slow drip during the next 8 hours.~Group C - A control group will only receive placebo in the emergency room and in the OR.
Study NCT00995137 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: NK Cell Infusion
Description: Infusing genetically modified NK cells into research participants who have chemotherapy refractory or relapse B-lineage ALL.
Study NCT04305964 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Nastent® (a distally perforated soft silicon nasal tube)
Description: Insertion of the Nastent® to nostril during sleep hours
Study NCT04305964 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Polygraphy with WatchPAT™ 300
Description: WatchPAT™ 300 is an innovative diagnostic Home Sleep Apnea Test (HSAT) that utilizes the proprietary Peripheral Arterial Tone signal (PAT™) to enable simple, accurate and reliable sleep apnea testing.
Study NCT04620109 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: KDR2-2
Description: KDR2-2 is a synthetic anti-angiogenic chemical compound with highly effective inhibition on vascular endothelial growth factor receptor-2 (VEGFR2), and an additional, moderate inhibitory effect on platelet-derived growth factor receptor β (PDGFRβ).~KDR2-2 suspension eye drop is in development for the treatment of corneal neovascularization.